Literature DB >> 2469389

Comparison of inhibitory activities of various antiretroviral agents against particle-derived and recombinant human immunodeficiency virus type 1 reverse transcriptases.

R F Schinazi1, B F Eriksson, S H Hughes.   

Abstract

Several known antiretroviral agents were tested for their ability to inhibit the activities of human immunodeficiency virus type 1 reverse transcriptase purified from virions or from a recombinant Escherichia coli strain. The recombinant reverse transcriptase, a polypeptide of 66 kilodaltons, showed inhibition profiles indistinguishable from those of the virion-derived enzyme with all tested compounds, except for suramin and two dextran sulfates. These were more inhibitory to the recombinant enzyme, presumably because the E. coli-derived enzyme was more highly purified. The relative ease with which large quantities of recombinant enzyme can be prepared should facilitate the large-scale screening and identification of new potential inhibitors of the human immunodeficiency virus type 1 reverse transcriptase.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2469389      PMCID: PMC171433          DOI: 10.1128/AAC.33.1.115

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  Inhibition of HTLV-III/LAV replication by foscarnet.

Authors:  P S Sarin; Y Taguchi; D Sun; A Thornton; R C Gallo; B Oberg
Journal:  Biochem Pharmacol       Date:  1985-11-15       Impact factor: 5.858

2.  Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV.

Authors:  F di Marzo Veronese; T D Copeland; A L DeVico; R Rahman; S Oroszlan; R C Gallo; M G Sarngadharan
Journal:  Science       Date:  1986-03-14       Impact factor: 47.728

3.  Dextran sulphate, a potent anti-HIV agent in vitro having synergism with zidovudine.

Authors:  R Ueno; S Kuno
Journal:  Lancet       Date:  1987-06-13       Impact factor: 79.321

Review 4.  Strategies for antiviral therapy in AIDS.

Authors:  H Mitsuya; S Broder
Journal:  Nature       Date:  1987 Feb 26-Mar 4       Impact factor: 49.962

5.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Adv Enzyme Regul       Date:  1984

6.  Delayed treatment with combinations of antiviral drugs in mice infected with herpes simplex virus and application of the median effect method of analysis.

Authors:  R F Schinazi; T C Chou; R T Scott; X J Yao; A J Nahmias
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

7.  Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells.

Authors:  H Mitsuya; D J Looney; S Kuno; R Ueno; F Wong-Staal; S Broder
Journal:  Science       Date:  1988-04-29       Impact factor: 47.728

8.  Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.

Authors:  P A Furman; J A Fyfe; M H St Clair; K Weinhold; J L Rideout; G A Freeman; S N Lehrman; D P Bolognesi; S Broder; H Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

9.  Expression and processing of the AIDS virus reverse transcriptase in Escherichia coli.

Authors:  W G Farmerie; D D Loeb; N C Casavant; C A Hutchison; M H Edgell; R Swanstrom
Journal:  Science       Date:  1987-04-17       Impact factor: 47.728

Review 10.  Suramin in the treatment of AIDS: mechanism of action.

Authors:  E De Clercq
Journal:  Antiviral Res       Date:  1987-01       Impact factor: 5.970

View more
  11 in total

1.  Structure-activity relationships and mode of action of 5-mercapto-substituted oligo- and polynucleotides as antitemplates inhibiting replication of human immunodeficiency virus type 1.

Authors:  T J Bardos; R F Schinazi; K H Ling; A R Heider
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

2.  Selective inhibition of human immunodeficiency virus type 1 replication by the (-) but not the (+) enantiomer of gossypol.

Authors:  T S Lin; R Schinazi; B P Griffith; E M August; B F Eriksson; D K Zheng; L A Huang; W H Prusoff
Journal:  Antimicrob Agents Chemother       Date:  1989-12       Impact factor: 5.191

3.  Synthesis and virucidal activity of a water-soluble, configurationally stable, derivatized C60 fullerene.

Authors:  R F Schinazi; R Sijbesma; G Srdanov; C L Hill; F Wudl
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

4.  Direct comparisons of inhibitor sensitivities of reverse transcriptases from feline and human immunodeficiency viruses.

Authors:  T W North; R C Cronn; K M Remington; R T Tandberg
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

5.  Illimaquinone, a selective inhibitor of the RNase H activity of human immunodeficiency virus type 1 reverse transcriptase.

Authors:  S Loya; R Tal; Y Kashman; A Hizi
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

6.  Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides.

Authors:  R F Schinazi; R M Lloyd; M H Nguyen; D L Cannon; A McMillan; N Ilksoy; C K Chu; D C Liotta; H Z Bazmi; J W Mellors
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

7.  Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates.

Authors:  J W Mellors; H Z Bazmi; R F Schinazi; B M Roy; Y Hsiou; E Arnold; J Weir; D L Mayers
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

8.  Anti-human immunodeficiency virus effects of dextran sulfate are strain dependent and synergistic or antagonistic when dextran sulfate is given in combination with dideoxynucleosides.

Authors:  M E Busso; L Resnick
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

9.  RNase H activity associated with reverse transcriptase from feline immunodeficiency virus.

Authors:  R C Cronn; J D Whitmer; T W North
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

10.  Phosphorylation of 3'-azido-2',3'-dideoxyuridine and preferential inhibition of human and simian immunodeficiency virus reverse transcriptases by its 5'-triphosphate.

Authors:  B F Eriksson; C K Chu; R F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.